Ya-Chi Chen
Chief Scientific Officer OBI Pharma, Inc.
Dr. Ya-Chi Chen is the Chief Scientific Officer at OBI Pharma. She holds a Doctor of Pharmacy degree from the University of Iowa and brings over 20 years of experience in drug development, specializing in clinical pharmacology and translational medicine. Her expertise covers small molecules, biologics, and antibody-drug conjugates across virology, immunology, and oncology.
A passionate advocate of science-driven, model-informed drug development (MIDD), Dr. Chen leverages translational insights and cross-functional collaboration to accelerate development and improve patient outcomes. She has held senior leadership positions at leading biopharmaceutical companies, including Executive Director at Revolution Medicines, Senior Director at Gilead Sciences, and Director at Roche.
Seminars
- Exploring rationale and design of OBI-221, a dual payload bispecific ADC targeting cMET/HER3
- Outlining lessons learned from pursuing a two hit, two target approach to guide future ADC innovation opportunities
- Evaluating initial characterization of OBI-221, contextualized with early clinical performance of TROP2 ADC leveraging same design principles
